Skip to main content
Erschienen in: Tumor Biology 10/2016

19.08.2016 | Original Article

MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma

verfasst von: Yue-yuan Lai, Fei Shen, Wen-Song Cai, Ji-wei Chen, Jian-hua Feng, Jie Cao, Huan-qing Xiao, Guang-hui Zhu, Bo Xu

Erschienen in: Tumor Biology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Acquired evidence indicated that microRNAs (miRNAs) played essential roles in cancer development, including hepatocellular carcinoma (HCC). Functions and mechanisms of miRNAs involved in HCC remain largely unknown. Here, we found that miR-384 was significantly downregulated in HCC cells and tissues by RT-PCR. Gain and loss of function studies revealed that miR-384 significantly suppressed HCC cell proliferation. Insulin receptor substrate 1(IRS1) was identified as a direct and functional target of miR-384. Moreover, miR-384 decreased IRS1 expression, subsequently downregulating cyclin D1 and upregulating p21 and p-Rb expression. In addition, promotion of cell proliferation caused by miR-384-in was counteracted by silencing IRS1 expression with siRNAs. Taken together, our data provided convincing evidence that miR-384 exerted suppressive effect on HCC cell proliferation through the direct inhibition of IRS1 expression, suggesting miR-384 may serve as a potential therapeutic target for HCC.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
Zurück zum Zitat Callegari E, Gramantieri L, Domenicali M, D’Abundo L, Sabbioni S, Negrini M. Micrornas in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ. 2015;22:46–57.CrossRefPubMed Callegari E, Gramantieri L, Domenicali M, D’Abundo L, Sabbioni S, Negrini M. Micrornas in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ. 2015;22:46–57.CrossRefPubMed
3.
Zurück zum Zitat Zhang Y, Huang F, Wang J, Peng L, Luo H. Mir-15b mediates liver cancer cells proliferation through targeting bcl-2. Int J Clin Exp Pathol. 2015;8:15677–83.PubMedPubMedCentral Zhang Y, Huang F, Wang J, Peng L, Luo H. Mir-15b mediates liver cancer cells proliferation through targeting bcl-2. Int J Clin Exp Pathol. 2015;8:15677–83.PubMedPubMedCentral
4.
Zurück zum Zitat Chang RM, Yang H, Fang F, Xu JF, Yang LY. Microrna-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting ph domain and leucine-rich repeat protein phosphatase. Hepatology. 2014;60:1251–63.CrossRefPubMed Chang RM, Yang H, Fang F, Xu JF, Yang LY. Microrna-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting ph domain and leucine-rich repeat protein phosphatase. Hepatology. 2014;60:1251–63.CrossRefPubMed
5.
Zurück zum Zitat Fu X, Meng Z, Liang W, Tian Y, Wang X, Han W, et al. Mir-26a enhances mirna biogenesis by targeting lin28b and zcchc11 to suppress tumor growth and metastasis. Oncogene. 2014;33:4296–306.CrossRefPubMed Fu X, Meng Z, Liang W, Tian Y, Wang X, Han W, et al. Mir-26a enhances mirna biogenesis by targeting lin28b and zcchc11 to suppress tumor growth and metastasis. Oncogene. 2014;33:4296–306.CrossRefPubMed
6.
Zurück zum Zitat Sun Z, Han Q, Zhou N, Wang S, Lu S, Bai C, et al. Microrna-9 enhances migration and invasion through klf17 in hepatocellular carcinoma. Mol Oncol. 2013;7:884–94.CrossRefPubMed Sun Z, Han Q, Zhou N, Wang S, Lu S, Bai C, et al. Microrna-9 enhances migration and invasion through klf17 in hepatocellular carcinoma. Mol Oncol. 2013;7:884–94.CrossRefPubMed
7.
Zurück zum Zitat Bai R, Weng C, Dong H, Li S, Chen G, Xu Z. Microrna-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting gab1 expression. Int J Cancer. 2015;137:2310–22.CrossRefPubMed Bai R, Weng C, Dong H, Li S, Chen G, Xu Z. Microrna-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting gab1 expression. Int J Cancer. 2015;137:2310–22.CrossRefPubMed
8.
Zurück zum Zitat Xing F, Sharma S, Liu Y, Mo YY, Wu K, Zhang YY, et al. Mir-509 suppresses brain metastasis of breast cancer cells by modulating rhoc and tnf-alpha. Oncogene. 2015;34:4890–900.CrossRefPubMedPubMedCentral Xing F, Sharma S, Liu Y, Mo YY, Wu K, Zhang YY, et al. Mir-509 suppresses brain metastasis of breast cancer cells by modulating rhoc and tnf-alpha. Oncogene. 2015;34:4890–900.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Zhang H, Li S, Yang X, Qiao B, Zhang Z, Xu Y. Mir-539 inhibits prostate cancer progression by directly targeting spag5. J Exp Clin Cancer Res. 2016;35:60.CrossRefPubMedPubMedCentral Zhang H, Li S, Yang X, Qiao B, Zhang Z, Xu Y. Mir-539 inhibits prostate cancer progression by directly targeting spag5. J Exp Clin Cancer Res. 2016;35:60.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Tan G, Wu L, Tan J, Zhang B, Tai WC, Xiong S, et al. Mir-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of nf-kappab signaling pathway. Sci Rep. 2016;6:22328.CrossRefPubMedPubMedCentral Tan G, Wu L, Tan J, Zhang B, Tai WC, Xiong S, et al. Mir-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of nf-kappab signaling pathway. Sci Rep. 2016;6:22328.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Sun JJ, Chen GY, Xie ZT. Microrna-361-5p inhibits cancer cell growth by targeting cxcr6 in hepatocellular carcinoma. Cell Physiol Biochem. 2016;38:777–85.CrossRefPubMed Sun JJ, Chen GY, Xie ZT. Microrna-361-5p inhibits cancer cell growth by targeting cxcr6 in hepatocellular carcinoma. Cell Physiol Biochem. 2016;38:777–85.CrossRefPubMed
12.
Zurück zum Zitat Tu K, Liu Z, Yao B, Han S, Yang W. Microrna-519a promotes tumor growth by targeting pten/pi3k/akt signaling in hepatocellular carcinoma. Int J Oncol. 2016;48:965–74.PubMed Tu K, Liu Z, Yao B, Han S, Yang W. Microrna-519a promotes tumor growth by targeting pten/pi3k/akt signaling in hepatocellular carcinoma. Int J Oncol. 2016;48:965–74.PubMed
13.
Zurück zum Zitat Song X, Wang Z, Jin Y, Wang Y, Duan W. Loss of mir-532-5p in vitro promotes cell proliferation and metastasis by influencing cxcl2 expression in hcc. Am J Transl Res. 2015;7:2254–61.PubMedPubMedCentral Song X, Wang Z, Jin Y, Wang Y, Duan W. Loss of mir-532-5p in vitro promotes cell proliferation and metastasis by influencing cxcl2 expression in hcc. Am J Transl Res. 2015;7:2254–61.PubMedPubMedCentral
14.
Zurück zum Zitat Zheng H, Zhang F, Lin X, Huang C, Zhang Y, Li Y, et al. Microrna-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of beta-catenin signaling. Oncotarget. 2016;7:4647–63.PubMed Zheng H, Zhang F, Lin X, Huang C, Zhang Y, Li Y, et al. Microrna-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of beta-catenin signaling. Oncotarget. 2016;7:4647–63.PubMed
15.
Zurück zum Zitat Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, et al. Microrna-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cmet pathway. Hepatology. 2014;59:1874–85.CrossRefPubMed Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, et al. Microrna-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cmet pathway. Hepatology. 2014;59:1874–85.CrossRefPubMed
16.
Zurück zum Zitat Li G, Yang F, Xu H, Yue Z, Fang X, Liu J. Microrna-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migration. Biomed Pharmacother. 2015;73:154–9.CrossRefPubMed Li G, Yang F, Xu H, Yue Z, Fang X, Liu J. Microrna-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migration. Biomed Pharmacother. 2015;73:154–9.CrossRefPubMed
17.
Zurück zum Zitat Liu H, Li W, Chen C, Pei Y, Long X. Mir-335 acts as a potential tumor suppressor mirna via downregulating rock1 expression in hepatocellular carcinoma. Tumor Biol. 2015;36:6313–9.CrossRef Liu H, Li W, Chen C, Pei Y, Long X. Mir-335 acts as a potential tumor suppressor mirna via downregulating rock1 expression in hepatocellular carcinoma. Tumor Biol. 2015;36:6313–9.CrossRef
18.
Zurück zum Zitat Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J, et al. Microrna-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer. 2010;46:2828–36.CrossRefPubMed Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J, et al. Microrna-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer. 2010;46:2828–36.CrossRefPubMed
19.
Zurück zum Zitat Hu S, Tao R, Wang S, Wang C, Zhao X, Zhao H, et al. Microrna-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting hepn1. Tumor Biol. 2015;36:5467–72.CrossRef Hu S, Tao R, Wang S, Wang C, Zhao X, Zhao H, et al. Microrna-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting hepn1. Tumor Biol. 2015;36:5467–72.CrossRef
20.
Zurück zum Zitat Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, Chen Y, et al. Microrna-185 suppresses tumor growth and progression by targeting the six1 oncogene in human cancers. Oncogene. 2010;29:4971–9.CrossRefPubMed Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, Chen Y, et al. Microrna-185 suppresses tumor growth and progression by targeting the six1 oncogene in human cancers. Oncogene. 2010;29:4971–9.CrossRefPubMed
21.
Zurück zum Zitat Cao M, Li Y, Lu H, Meng Q, Wang L, Cai L, et al. Mir-23a-mediated migration/invasion is rescued by its target, irs-1, in non-small cell lung cancer cells. J Cancer Res Clin Oncol. 2014;140:1661–70.CrossRefPubMed Cao M, Li Y, Lu H, Meng Q, Wang L, Cai L, et al. Mir-23a-mediated migration/invasion is rescued by its target, irs-1, in non-small cell lung cancer cells. J Cancer Res Clin Oncol. 2014;140:1661–70.CrossRefPubMed
22.
Zurück zum Zitat Su W, Xu M, Chen X, Nie L, Chen N, Gong J, et al. Mir200c targets irs1 and suppresses prostate cancer cell growth. Prostate. 2015;75:855–62.CrossRefPubMed Su W, Xu M, Chen X, Nie L, Chen N, Gong J, et al. Mir200c targets irs1 and suppresses prostate cancer cell growth. Prostate. 2015;75:855–62.CrossRefPubMed
Metadaten
Titel
MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma
verfasst von
Yue-yuan Lai
Fei Shen
Wen-Song Cai
Ji-wei Chen
Jian-hua Feng
Jie Cao
Huan-qing Xiao
Guang-hui Zhu
Bo Xu
Publikationsdatum
19.08.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 10/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5233-5

Weitere Artikel der Ausgabe 10/2016

Tumor Biology 10/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.